# **BMJ Open** What matters to patients with multiple sclerosis? Identifying patient-relevant attributes using a ranking exercise with open-ended answers from an online survey in Italy

Karin Schölin Bywall <sup>(b)</sup>, <sup>1,2</sup> Ulrik Kihlbom,<sup>3</sup> Jennifer Viberg Johansson,<sup>2,4</sup> Guido Pasquini,<sup>5</sup> Filippo Gerli,<sup>5</sup> Claudia Niccolai,<sup>5</sup> Sara Della Bella,<sup>5</sup> Emilio Portaccio,<sup>6</sup> Matteo Betti,<sup>6</sup> Maria Pia Amato,<sup>7</sup> Sylvia Martin<sup>8</sup>

#### ABSTRACT

**Objectives** This study aimed to explore what intervention specificities or attributes newly diagnosed individuals with multiple sclerosis (MS) find important and to explore possible reasons behind their evaluations.

**Design** A stepwise approach began with a systematic literature review to identify significant attributes. Patients with MS then assessed these attributes through an online survey, which included a ranking exercise and open-ended questions. Finally, the results were evaluated by the clinical team to select the most relevant factors for personalised care.

Setting and participants From June 2023 to December 2023, all consecutive patients referred to the MS Center of Careggi University Hospital were screened for inclusion. Following recruitment, cognitive and physical assessments were administered at the Don Gnocchi Centre. All participants were interviewed by an experienced neuropsychologist.

Procedures Participants were enrolled in the RELIABLE clinical trial, which included a ranking exercise and openended question. In the ranking exercise, patients prioritised levels of treatment attributes: treatment effects, methods of intervention, type of monitoring, monitoring, mode and mental support. The open-ended questions addressed the reasons behind the level rankings.

Results Participants' rankings revealed the most important levels of each attribute. The highest-ranked method of intervention was disease-modifying treatment, which received 164 points. For mental support, individual psychotherapy was deemed most important with 149 points. Preservation of cognitive function, a key treatment effect, received 144 points. Clinical check-ups were the top type of monitoring with 129 points. Lastly, the hybrid mode of monitoring (half remote/half in-person) was ranked with 77 points. Open-ended responses provided insights into the reasons behind these preferences, emphasising the importance of maintaining mobility, cognitive function and emotional well-being. The clinical team evaluated these findings, confirming that the selected attributes were both clinically relevant and aligned with patient priorities. This evaluation process

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- $\Rightarrow$  The study used a stepwise approach, combining a systematic literature review, quantitative ranking and qualitative insights, ensuring a thorough exploration of treatment attributes.
- $\Rightarrow$  The evaluation of results by the clinical team ensured that the selected treatment attributes were both clinically relevant and aligned with patient priorities.
- $\Rightarrow$  Open-ended responses provided valuable insights into the reasons behind patient preferences, highlighting the importance of maintaining mobility, cognitive function and emotional well-being.
- $\Rightarrow$  A limited number of patients with multiple sclerosis participated in the ranking exercise, potentially affecting the generalisability of the results.

ensured that the treatment specificities chosen for individualised care were comprehensive and reflective of patient needs.

**Conclusions** By identifying and prioritising key treatment attributes, this research highlights the multifaceted nature of MS management and emphasises the importance of aligning treatment options with patient preferences. Addressing these factors through further quantitative preference assessments is essential for preventative MS care, improving patient outcomes and promoting a more patient-centred approach to treatment.

#### INTRODUCTION

Multiple sclerosis (MS) is a chronic neurological disease that impacts the central nervous system.<sup>1</sup> It is one of the most common neurological conditions among young adults (aged 18-40 years), with a prevalence of approximately 2.8 million people worldwide and an incidence that varies geographically.<sup>2</sup> Characterised by its unpredictable nature and a wide range of symptoms, MS poses a substantial

and

data mining, Al training, and similar technologies

To cite: Bywall KS, Kihlbom U, Johansson JV, et al. What matters to patients with multiple sclerosis? Identifying patient-relevant attributes using a ranking exercise with open-ended answers from an online survey in Italy. BMJ Open 2025;15:e095552. doi:10.1136/ bmjopen-2024-095552

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-095552).

Received 24 October 2024 Accepted 09 May 2025



C Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

For numbered affiliations see end of article.

**Correspondence to** Karin Schölin Bywall; karin.bywall@crb.uu.se challenge for both patients and healthcare providers.<sup>3</sup> MS is an inflammatory disease where immune cells attack and damage the myelin sheath and nerve fibres in the brain and spinal cord.<sup>4</sup> Initially, the inflammation can heal, causing symptoms to come and go. However, over time, the damage becomes more extensive and permanent, leading to a gradual increase in disability. MRI scans are fundamental for establishing diagnosis and for evaluating treatment response.

MS is triggered by environmental factors in individuals with certain genetic risks.<sup>5</sup> Current medications reduce the frequency of new episodes but cannot repair existing damage and partially fail to stop progression independent from relapse activity.<sup>6</sup> Future research aims to improve treatment by focusing on the underlying mechanisms of the disease.<sup>7</sup> As a lifelong condition, MS necessitates ongoing medical supervision and treatment, tailored to the individual's specific needs and the progression of the disease.<sup>8</sup> The interventions for MS are diverse, encompassing disease-modifying therapies, symptomatic treatments, rehabilitation and lifestyle modifications.<sup>9</sup>

Given the chronic and unpredictable nature of MS, it is crucial to thoroughly assess and comprehend the treatment specifics (also called attributes) that are most important for individuals living with the condition.<sup>10</sup> In preference studies, an attribute is a characteristic or feature of something being evaluated; it is a specific aspect that can vary and influence a person's choices. For example, it can be viewed as a quality that helps to compare different options, such as the price or colour of a product. Researchers use these attributes to understand how people weigh different factors when making decisions. These attributes considered in one's decision making can vary significantly from person to person, influenced by their symptoms, disease progression, personal preferences and lifestyle.<sup>11</sup> Recognising these critical factors is essential for tailoring a more personalised and patient-centred approach to MS care.<sup>12</sup> This approach not only enhances treatment effectiveness but also enables collaborative decision-making between patients and healthcare providers regarding the most suitable treatment options at each stage of the disease. Such collaboration is vital for fostering patient ownership and adherence to the treatment regimen.<sup>13</sup>

Furthermore, early prevention strategies play a crucial role in mitigating the risk of MS development.<sup>14</sup> By identifying and addressing risk factors and promoting healthy lifestyle choices, it is possible to reduce the likelihood of MS onset or delay its progression. Therefore, incorporating preventive measures into MS care plans is imperative for improving long-term outcomes and the overall quality of care.

This study was part of the RELIABLE project (Vinnova (ERA-permed project) 2022-00564), which aimed to assess the subclinical burden of neurological impairments in early relapsing-remitting MS patients with no evident neurological disability (Expanded Disability Status Scale (EDSS) score of 2.0 points or less). This comprehensive

S

assessment includes comorbidities, lifestyle, imaging, neuropsychological, gait and balance analyses. Additionally, the RELIABLE project seeks to understand patient preferences, which serves as motivation for this study. A clinical trial part of the project is dedicated to the definition of risk-based classification for newly diagnosed patients, integrating patients' preferences in the research. This study aimed to explore what intervention specificities or attributes newly diagnosed individuals with MS find important and to explore possible reasons behind their evaluations.

#### **METHODS**

#### Participants and recruitment

Protected by copyrig Patients referred to the MS Center of Careggi University Hospital were consecutively recruited for the RELIABLE project. Cognitive and physical assessments, as well as interviews, were conducted at the Don Gnocchi Centre. Screening for inclusion took place from June 2023 to December 2023. The inclusion criteria were based on a diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 McDonald criteria, age of r uses 18 years or older, an EDSS score of 2.0 or lower and a disease duration of 5 years or less. Verification of the MS subtype, disease duration and EDSS were accomplished by obtaining a signed consent form for the release of medical information from the treating neurologist. Psychiatric and substance abuse histories were obtained via interviews and verified by medical records.

Exclusion criteria included a history of relevant psychiatric comorbidities that might compromise understanding of the test and clinical scales, relapses or  $\overline{\mathbf{s}}$ corticosteroid treatment within 30 days before inclusion, a history of substance abuse and the presence of non-MS related physical or cognitive impairments that could prevent completion of the study assessments. Participants were selected from patients referred for diagnosis and/ or treatment at Careggi University Hospital. Enrolment was based on consecutive recruitment at the centre for the RELIABLE clinical trial. The estimated sample size needed to observe a relevant effect in the clinical trial was 70 patients. Therefore, the targeted sample size for this side study, which included the ranking exercise and open-ended questions, was set to include all 70 patients. technologies We used the Checklist for Reporting Of Survey Studies to guide reporting of the survey results (online supplemental file 1).

#### **Stepwise approach**

Starting with a literature review (step 1) to identify important treatment attributes for newly diagnosed patients with MS. The literature review revealed key themes: (1) differences emerged between healthcare professionals' and patients' perspectives, (2) interventions for MS outside disease-modifying therapies (DMTs), (3) severe side effects, (4) communication, information and knowledge and (5) psychological and emotional factors.<sup>1 5 8 10 11 15-23</sup> This specific literature review and its methods have been published separately.<sup>24</sup>

Thereafter, in step 2, a list of possibly patient-relevant attributes was further assessed by patients diagnosed with MS. In this step, patients who were enrolled in the RELI-ABLE project were invited to sit together with a healthcare professional and answer an online questionnaire (see all survey items in online supplemental file 2). The questionnaire was developed in English by the whole team and then translated to Italian in order to be coded in the secure data collection system RedCap (pretesting was performed by native Italian speakers at Don Gnocchi). The questionnaire was filled in to the RedCap system (verbatim) by the researcher after the patient responded to the questions in the questionnaire to protect anonymity and avoid data extraction from general records from the patient's information in the general record system. The questionnaire included both a quantitative ranking exercise to assess the most important treatment aspects of the ones identified in step 1 and open-ended questions for patients to present the reasons behind their choices. Participants answered the questions via a sheet of paper when visiting the Don Gnocchi Foundation outpatient clinic, and the interviewer transcribed verbatim their 'open comment' on the final section of each item. Finally, in step 3, the results were discussed and evaluated within the clinical team of the RELIABLE project to select the most clinically and patient-relevant treatment attribute to individualise treatment for newly diagnosed patients with MS. As the preferences are designed here to be eliciting

preferences (based on the current situation) and not exploring (potential scenarios), health care professionals (HCPs) were asked to define the current situation for the Italian setting and the most realistic treatment option that an MS patient will face in the clinic.

#### Quantitative ranking exercise of potential aspect level

Individuals diagnosed with MS (n=70) were asked to answer five different ranking questions. Each question with a theme representing a potential treatment attribute. The potential attributes included were treatment effects, methods of intervention, type of intervention, monitoring mode and mental support. Each question ş included three to four different potential levels of attributes to be ranked by its importance by the respondents (table 1).

copyright, including Before disseminating the survey, experts' interviews were used to refine the content and exact working through two workshops and two rounds of written reviews.

#### **Qualitative open-ended questions**

During the primary data collection stage of the RELI-ABLE project, when newly diagnosed patients with MS were enrolled, they participated in several clinical tests for their physical condition. They were also assessed regarding their cognitive and psychological state. During these interviews with the neuropsychologist, participants were asked to perform a ranking task, and the neuropsychologist entered their answer in a specially designed digital platform. The platform was used to collect data

Table 1         Ranking exercise of potential attribute levels					
Potential attribute	Questions asked to patients	Potential attribute levels that were ranked			
Treatment effects	Which effects are the most important for you?	<ul> <li>Prevention of disability progression (chance of reducing the progression of MS symptom progression)</li> <li>Preservation of cognitive function (memory, processing speed, verbal fluency and executive functions)</li> <li>Preservation of mobility abilities (motor functions and autonomy)</li> <li>Preservation of psychosocial engagement (go to work, family time, love life and social interaction)</li> </ul>			
Methods of intervention	Which method of intervention are you willing to try first?	<ul> <li>Treatment with disease modifying drugs (DMDs, pills, injection)</li> <li>Lifestyle changes (diet, better sleep, stress management, smoking interruption and alcohol interruption)</li> <li>Exercise (physiotherapy, walking and sports)</li> </ul>			
Type of monitoring	Which type of monitoring would you like the most?	<ul> <li>Self-monitoring</li> <li>Clinical check-ups</li> <li>Caregivers monitoring (family member, partner)</li> </ul>			
Monitoring mode	Which monitoring mode would you like best?	<ul> <li>Remote (App/online and phone call/SMS)</li> <li>In-person (clinical centre, GP)</li> <li>Hybrid (in person+online)</li> </ul>			
Mental support	What type of mental support is more important for you?	<ul> <li>Individual psychotherapy (with a psychologist)</li> <li>Group psychotherapy</li> <li>Psychological support (other healthcare professional)</li> <li>Neuropsychology (brain training)</li> </ul>			

BMJ Open: first published as 10.1136/bmjopen-2024-095552 on 23 May 2025. Erasmu asmushogeschool Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Department GEZ-LTA

tor uses related

6

text

for both the ranking exercise and open-ended questions, which the neuropsychologist was tasked with recoding verbatim while interacting with the participant.

The open-ended answers were analysed by inductive qualitative content analysis of the open-ended questions.<sup>25</sup> All open-ended answers corresponded to the question 'Why did you choose this ranking?' for each attribute ranking task (O1, Which effects are the most important attribute for you? Q2. Which method of intervention are you willing to try first? Q3. Which type of monitoring would you like the most? Q4. Which monitoring mode would you like best? Q5. What type of mental support is more important for you?). The answers were varying in lengths from the shortest being of three words ('Trust in therapy') to the largest being of 99 words (larger explanation about the participants' experiences with DMT motivating their choice for ranking DMT higher).

Each transcript was initially analysed independently. In qualitative content analysis, the process began with open coding, where SM and KSB read through the text, making notes and headings to capture the content. These headings were then categorised. Subsequently, categories were created by grouping related observations under higher-order headings to provide meaningful classification. Finally, the abstraction phase involved generating and naming categories, grouping similar subcategories together and continuing this process until a comprehensive understanding was achieved.

## **Evaluating clinical relevance**

The first clinical evaluation was operationalised as a discussion at a digital RELIABLE project meeting. During the meeting, the results of the ranking exercise were presented. Thereafter, the clinical relevance of the top selected aspect levels was selected for further analysis. Additionally, the members of the meeting were asked to provide written feedback after the meeting to serve as input for further aspect and aspect level selection and framing.

# **Statistical analysis**

All data were extracted in Excel, and the analysis was conducted using this software. For the analysis of the ranking exercise, the numbers were reversed. The most important level of an attribute received the highest score (ie, the top ranked attribute number 1 received the highest score 3 or 4, depending on the number of levels that were ranked). We present the normalised scores (total score for each level/max (total score))×100 for each attribute.

#### Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

#### RESULTS

#### **Respondent characteristics**

The quantitative ranking exercise of treatment aspect levels, along with the open-ended questions, was completed by 52 out of the targeted 70 respondents,

Table 2 Descriptive statistics of respondent's demographic characteristics

Demographics	Participants n=52		
Age (years)			
Mean (SD)	36.2 (10.3)		
Median (min, max)	36.5 (21, 63)		
Gender			
Female	36 (72%)		
Male	14 (28%)		
Years of schooling			
8	4 (8.0%)		
13	19 (38%)		
14	1 (2%)		
15	3 (6%)		
16	9 (18%)		
18	14 (28%)		
Years since diagnosed with MS			
6 years with MS	1 (2%)		
4 years with MS	8 (16%)		
3 years with MS	11 (22%)		
2 years with MS	15 (30%)		
1 year with MS	10 (20%)		
<1 year with MS	5 (10%)		
MS, multiple sclerosis			

Protected by copyright, including for uses related to text and data mining, AI training, resulting in a response rate of 74%. The mean age of the respondents was 36 years (SD 10.3). Most of the respondents were women (72%). All the respondents were clinically diagnosed with MS and received their MS diagnosis between the years 2017 and 2023 (table 2).

# **Attribute level rankings**

The aspect level rankings were completed by 41 out of the 52 participants (79%) (figure 1). Three participants did not complete the ranking exercise as they were recruited before the implementation of the final design. One participant did not provide a ranking for one item, and the score for this item was not considered. One participant did not answer all the 'open-ended questions', but ē the ranking score was kept.

Levels of potential treatment attributes were ranked separately for each attribute. Within the potential attribute (1) mental support, individual psychotherapy was **3** the highest ranked aspect level by 149 points, followed by neuropsychology with 134 points, psychological support with 107 points and group psychotherapy with 99 points. In aspect (2) monitoring mode, hybrid mode (half remote/half in person) was the most highly ranked level with 77 points, followed by in-person with 63 points and remote with 54 points. In aspect (3) type of monitoring, clinical check-ups were the highest ranked aspect level by 129 points. In aspect (4) methods of intervention, disease







modifying treatment was the highest ranked aspect level by 164 points, followed by lifestyle modification with 128 points and, closely followed by exercise with 121 points. In aspect (5) treatment effects, the highest ranked aspect level was preservation of cognitive function with 144 points, then prevention of disability with 138 points and then preservation of psychosocial engagement with 89 points. For all points description, see figure 1.

#### **Reasons behind aspect rankings**

Results of the qualitative content analysis revealed that respondents made their choices based on their right to impact treatment decisions, trust in the healthcare system, their self-image, side effects and psychosocial aspects (table 3).

#### Right to impact treatment decisions

In order to feel that quality of life is not impaired by MS, treatment needs to fit into the individual's current lifestyle and not depend on caregivers or family members to sustain their way of living.

## Trust in the healthcare system

Individuals trust the HCPs expertise and guidance, relying on the fact that offered treatments or medication are accurate and efficient. Medical and scientific advice are considered first as elements to address the severity and produce the best benefits.

#### Side effects

Individuals want to avoid harm and suffering.

#### Self-image

During the course of illness or course of treatment, individuals want to maintain their identity (self) and still be themselves internally.

#### Psychosocial aspects

Individuals express emotions and need for support or social connection to talk about MS and their experience.

## **Clinical evaluation**

data mining, Al training, The results from the ranking exercise and open-ended questions to explore treatment attributes important to patients and reasons behind their evaluations were discussed among the research team of the RELIABLE project for clinical evaluation. The clinical evaluation consisted of the authors, that is, persons working with patients with MS as healthcare professionals (medical chnolog doctor, physiotherapists and neuropsychologist), and researchers specialised in preferences studies (psychologist, ethicist and health scientist).

The clinical evaluation resulted in four new attributes  $\overline{\mathbf{g}}$ with associated levels. Each aspect was selected based on being both clinically and patient relevant (table 4).

# Physical activity

Physical activity was selected on the basis that it was a real option for MS patients enrolled in the RELIABLE project. Physical activity will be recommended to all patients to prevent the progression of MS. The selected levels were (1) resistance training, (2) stretching (eg, yoga,

Protected by copyright, including for uses related to text and

	Supcatedory	Categories	Reasons behind choices
'l would prefer to do everything independently and always be followed up through clinical checkups."	Maintaining autonomy	Right to impact treatment decisions	I want the right to impact treatment decisions
'I chose this sequence because it corresponds more or less to what I already do"	Habits Convenience		
'I would not want to burden my loved ones"	Protect others		
'The most important thing is that the disease does not progress. Then it's all together, a whole sequence of things.'	, Time		
Family monitoring sees situations but is not objective; there s too much involvement, because sometimes we tend to be nfluenced by some feelings that have nothing to do with the ssue"	e Objectivity e	Trust in healthcare system	I trust the healthcare system
Doctors are the ones you have to trust the most" "The doctor is the best person who can perform these kinds of checks"	Trust		
'Medical monitoring is the most authoritative"	Believe		
'The important thing for me is to feel as little as possible the presence of this disease in my life and the difference between me and anyone else who does not have multiple sclerosis"	Identity	Self-image	I want to stay the same as before my MS diagnosis
Because I don't want to lose myself and not be able to do the things I always do. The progression of the disease is nevitable, but I would like to be able to remain the person I am for as long as possible"	Protect self- image		
Because the safeguarding of cognitive functioning is the safeguarding of my personality"	Self-perception		
'This order is the best for me"	Self-confidence		
'I can't stand the pains"	Fear of pain	Side effects	I want to avoid side effects
'These are all side effects that I am not willing to accept. The multiple sclerosis already seems to me to be enough."	Avoiding side effects		
a group discussion would help me better understand my problem by comparing myself with other people who can understand my discomforts without perhaps judging me" 'It is important for me to see and talk to people without the filter of a computer unless it is necessary"	Warmth	Psychosocial aspects	l want to maintain my socia life
'I would look for comparison with those around me in this area, because they are already in it."	Group belonging		
Because I am not afraid of the psychosocial aspect of which I feel very calm and secure the rest yes" "They are all mportant, however with medication I am calmer" "Based or my fears"	Emotions		
MS multiple sclerosis			

pilates) and (3) aerobic training. Physical activity was also selected on the basis of being an accepted alternative by MS patients. As the results from the ranking exercise by MS patients revealed, physical activity (ie, exercise) was preferred over both lifestyle changes (ie, diet, better sleep, stress management, smoking interruption and alcohol interruption) and disease modifying drugs.

# Cognitive training

The selection of cognitive training as an aspect was based on available treatment options for newly diagnosed

training, (2) group exercise together with other MS patients and (3) individual neuropsychology with therapist (cognitive rehabilitation), even if 'preservation of cognitive function' was the lowest ranked aspect level out of the different levels of treatment effects. The reasons behind respondents' choices in the ranking exercise were based on self-image and the desire to stay the same as before the MS diagnosis. Therefore, cognitive training

Table 4         Final list of attributes and attribute levels					
Final attributes after expert evaluation	Final levels				
Physical activity	<ul> <li>Resistance training.</li> <li>Stretching (eg, yoga, pilates).</li> <li>Aerobic training.</li> </ul>				
Cognitive training	<ul> <li>Individual home-based computerised training.</li> <li>Group exercise together with other MS patients.</li> <li>Individual neuropsychology with therapist (cognitive rehabilitation).</li> </ul>				
Disease modifying drugs	<ul> <li>Disease modifying drug (everyday pill).</li> <li>Short course of pills (eg, 2 weeks per year).</li> <li>In-hospital infusions (every month or every 6 months).</li> <li>Wait to start with disease-modifying drugs, to follow-up with new assessment after 6 months.</li> </ul>				
Emotional support	<ul> <li>Individual psychotherapy.</li> <li>Group psychotherapy.</li> <li>Psychological counselling (other healthcare professional).</li> </ul>				
Treatment effects	<ul> <li>Preservation of cognitive function.</li> <li>Preservation of mobility abilities.</li> <li>Preservation of quality of life.</li> </ul>				
MS, multiple sclerosis	5.				

was selected on the basis of being both clinically relevant and relevant by the patients.

# Disease modifying drugs

Aspect levels selected were (1) disease modifying drug (everyday pill), (2) short course of pills (eg, 2 weeks per year), (3) in hospital infusions (every month or every 6 months) and (4) wait to start with disease modifying drugs, to follow-up with new assessment after 6 months. This decision was based on the alternatives provided to patients that were enrolled in the RELIABLE study.

# **Emotional support**

The initially assessed aspect levels for Mental support were revised into Emotional support after the qualitative analysis and evaluation round. The rationale for the change of the framing was the clinical relevance as it is more in line with the framing of the clinicians in Italy. The selected aspect levels were (1) individual psychotherapy, (2) group psychotherapy and (3) psychological counselling (with other healthcare professionals).

# Treatment effects

The initial attribute Treatment effects was kept after the ranking exercise and the evaluation round. The aspect levels were revised from four to three by mainly focusing on preservation, excluding prevention. The rationale for mainly focusing on preservation was due to the reasons behind respondents' choices to 'stay the same as before my MS diagnosis'. Therefore, the selected attribute levels were (1) preservation of cognitive function, (2) preservation of mobility abilities and (3) preservation of quality of life. For full description, see table 4.

# DISCUSSION

The aim of this study was to explore what intervention 2 specificities or attributes newly diagnosed individuals with MS find important and to explore possible reasons behind their evaluations. This study outlined a stepwise 9 approach that consisted of three steps. Step 1 was a literature review to identify important treatment specificities for newly diagnosed patients with MS. Step 2 was a quantitative ranking exercise, where patients with MS ranked a list of possibly patient-relevant factors. Finally, in step 3, the results of steps 1 and 2 were evaluated within the clinical team of the RELIABLE project to select the most clinically and patient-relevant treatment attributes for individualised treatment for newly diagnosed patients with MS. Within this procedure, five treatment aspects, with three to four levels each, were identified as being <u>6</u> relevant for patients and clinicians.

The analysis revealed distinct preferences across five key treatment aspects. First, regarding mental support, individual psychotherapy was most highly valued. Second, for monitoring mode, a hybrid approach (half remote/half in-person) was preferred over in-person or remote-only options. Third, clinical check-ups were favoured. Fourth, disease-modifying treatment was the most desired intervention method, even at this early stage of the disease. Finally, preservation of cognitive function and prevention of disability were the most highly ranked treatment effects.

The final attributes selected were: physical activity, cognitive training, disease modifying drugs, emotional support and treatment effectiveness. The results from the ranking exercise were in line with previous research in the same field regarding preferences among patients with MS.<sup>10 11 13 26-29</sup> This departure from solely quantifiable or directly comparable attributes acknowledges the complex interplay of clinical and psychosocial factors inherent in MS management. The MS field appeared to be conservative about drug-based and classical clinical checkups expectation by the patient even at early stages of the disease when it may not be clinically needed, showing that education and communication about MS are needed.

Indeed, qualitative research also showed similar views of patients who do not see the interest of the long-term vision of their disease, for example, struggling with advance care planning at later stages. Even if good options for remote care exist,<sup>30</sup> patients reported struggles, and when interrogated about the need for improvements, they clearly expressed the importance of getting more guidance and to ensure that they will get all the

needed information to be transferred to their clinician, that they will favour digital equipment that will help them monitor their health and maintain access to local clinic with online facilities linking them to their specific care team (first 3 out of 8 items).<sup>31</sup> A suggestion for further research is to account for these specific attributes when offering remote or hybrid options to MS patients. It is also notable that patients themselves identified the need for cognitive function preservation to be a priority even at early stages,<sup>32</sup> confirming the current rise of interest in refined evaluation of minimal changes.<sup>33</sup> But also the use of targeted interventions using different techniques, from therapy to exercise<sup>34 35</sup> or different types of cognitive rehabilitation techniques (computer based, manual based or combined) was observed.<sup>30</sup>

Recently, reviews about clinical outcomes in MS still did not include specific measures of social connectivity,<sup>37</sup> continuing the tradition of measuring optical, motor, balance, sensory or cognitive symptoms.<sup>38</sup> Further research could encourage the use of social connectedness measures like the revised Social Connectedness Scale.<sup>39</sup>

The results for this study may be used for a future quantitative preference assessment in MS to assess the relative importance of treatment attributes and preference heterogeneity.<sup>40</sup> While previous preference studies in MS have mainly focused on drug development, such as the work by Lynd *et al*,<sup>41</sup> the results of this study imply that patients consider treatment attributes related to preventative treatment, such as individual psychotherapy, preservation of cognitive function and clinical check-ups, to be important for their preferences of MS care. By integrating patient perspectives by assessing patient preferences and clinical insights, the research highlights the need for a personalised approach to MS care. This approach not only aligns treatment options with patient preferences but also addresses the multifaceted nature of MS management.

A strength of this study was the explorative stepwise approach that included a systematic literature review, patients with MS, healthcare professionals working with MS patients and preferences of researchers aligning with the stepwise method approach that expanded in the social sciences field, representing the excellence of preference studies across fields.<sup>42 43</sup> A limitation of this study may have been the limited number of included patients with MS in the recruitment for the ranking exercise (n=41). Therefore, the results of this study may not be generalisable to the general MS population in Italy. However, we suggest further assessing patients' preferences for the identified MS treatment attributes in this study within a bigger patient sample and with a more robust preference elicitation method. Thereafter, it may be possible to draw conclusions on what treatment attributes MS patients in Italy prefer.

Additionally, the study also reveals gaps in current research, particularly in understanding how to effectively tailor treatments to individual needs and preferences, as most of the research focused on disease-modifying BMJ Open: first published as 10.1136/bmjopen-2024-095552 on 23 May 2025. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Department GEZ-LTA

treatment.<sup>11 44</sup> These insights pave the way for further investigation into optimising MS care, ensuring that treatment plans are both patient-centred and evidencebased when literature showed the importance of different factors influencing patient preferences in MS.<sup>45</sup> Additionally, further research is required for the development of methods to quantitatively assess patient-relevant benefits and risks to support shared decision-making in treatment plans.<sup>29</sup>

A key innovation lies in the study's explicit focus on a **\_** drug-centric paradigm, even if preventative measures are more and more emphasised and gaining more recogni-tion as adequate intervention and most relevant personalised care in MS.<sup>46</sup> This is counterintuitive regarding the patient preferences for non-pharmacological inter- 8 ventions, such as lifestyle modifications and cognitive yraining.<sup>47</sup> The study's findings, particularly the low granking of psychosocial engagement preservation, underranking of psychosocial engagement preservation, underscoring the lack of importance of quality-of-life considerations in MS care,<sup>48</sup> may be due to the fact that they are often overlooked in traditional clinical trials. For Бu example, in a recent systematic review about quality of for uses related to text life aspects in MS, only two papers among 106 mentioned the importance of social aspects.<sup>49</sup>

#### **CONCLUSIONS**

By identifying treatment attributes such as physical activity, cognitive training, disease-modifying drugs, emotional support and treatment effectiveness as key for patients, the research underscores the multifaceted nature of MS analysis management. However, the study also reveals significant the research underscores the multifaceted nature of MS gaps in current research, particularly in tailoring treat- ∃ ments to individual needs and preferences, and developing quantitative methods to assess patient-relevant Al training, and similar technologies benefits and risks. Addressing these gaps through further research is essential for advancing MS care, improving patient outcomes and promoting a more patient-centred approach to treatment.

#### Author affiliations

<sup>1</sup>Department of Public Health Sciences, Mälardalen University, Vasteras, Sweden <sup>2</sup>Centre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden <sup>3</sup>Department of Learning, Informatics, Management and Ethics, Karolinska Institute Stockholm, Sweden

<sup>4</sup>Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

<sup>5</sup>IRCCS Don Gnocchi Hospital, Firenze, Italy

<sup>6</sup>AOUC, Firenze, Italy

<sup>7</sup>Neuroscience, University of Florence, Firenze, Italy

<sup>8</sup>Uppsala University, Uppsala, Sweden

Contributors KSB is responsible for the overall content as guarantor. All authors have contributed to the planning, execution and reporting of the work. Specific contributions are as follows. KSB, UK, JVJ and SM: conceptualisation and design of the study. GP, FG, CN and SDB: data collection and analysis. EP, MB and MPA: clinical advice and validation of results. All authors have read and approved the final version of the manuscript.

Funding This work was supported by Vinnova (ERA-permed project) grant number 2022-00564.

**Competing interests** MPA has received research grants by the National MS Society, Canadian MS Society, Italian Health Ministry, Regione Toscana, Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall and Roche and honoraria as a speaker and member of advisory boards by Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, Roche, Celgene BMS and Amgen. All other authors have no competing interest to declare.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

#### Patient consent for publication Not applicable.

Ethics approval This study involves human participants and the data sharing and handling of all tasks of the RELIABLE project regarding preferences and patient questionnaires have been granted to Uppsala University via the Swedish Ethical Review Authority (2023-05818-01), and Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana (24121-PF-31\_05\_2023) approved the recruitment and clinical procedure for domestic experiments in Italy. All participants provided informed consent to participate in the RELIABLE project including the survey with the ranking task.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data will be made available under reasonable demand by the corresponding authors.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID iD**

Karin Schölin Bywall http://orcid.org/0000-0002-5865-5590

#### REFERENCES

- 1 Compston A, Coles A. Multiple sclerosis. *Lancet* 2008;372:1502–17.
- 2 Walton C, King R, Rechtman L, *et al.* Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult Scler* 2020;26:1816–21.
- Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. *Lancet* 2017;389:1336–46.
   Oh J, Vidal-Jordana A, Montalban X, Multiple sclerosis: clinical
- Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. *Curr Opin Neurol* 2018;31:752–9.
   Dobson B, Giovannoni G, Multiple sclerosis - a review. *Fur J Ne*
- 5 Dobson R, Giovannoni G. Multiple sclerosis a review. *Eur J Neurol* 2019;26:27–40.
- 6 Doshi A, Chataway J. Multiple sclerosis, a treatable disease. *Clin Med (Lond)* 2016;16:s53–9.
- 7 Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 2023;22:78–88.
- 8 Thompson AJ, Baranzini SE, Geurts J, *et al*. Multiple sclerosis. *Lancet* 2018;391:1622–36.
- 9 Jakimovski D, Bittner S, Zivadinov R, et al. Multiple sclerosis. Lancet 2024;403:183–202.
- 10 Visser LA, Louapre C, Uyl-de Groot CA, et al. Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Mult Scler Relat Disord 2020;39:S2211-0348(20)30005-5.
- 11 Jonker MF, Donkers B, Goossens LMA, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. *Med Decis Making* 2020;40:198–211.
- 12 Rieckmann P, Boyko A, Centonze D, et al. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. *Mult Scler Relat Disord* 2015;4:202–18.
- 13 Poulos C, Wakeford C, Kinter E, et al. Patient and physician preferences for multiple sclerosis treatments in Germany: A

discrete-choice experiment study. *Mult Scler J Exp Transl Clin* 2020;6:2055217320910778.

- 14 Marrie RA, Allegretta M, Barcellos LF, et al. From the prodromal stage of multiple sclerosis to disease prevention. Nat Rev Neurol 2022;18:559–72.
- 15 Poulos C, Kinter E, Yang J-C, et al. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. *Ther Adv Neurol Disord* 2016;9:95–104.
- 16 Reeve K, On BI, Havla J, et al. Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. *Cochrane Database Syst Rev* 2023;9:CD013606.
- 17 Thompson B, Moghaddam N, Evangelou N, et al. Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis. *Mult Scler Relat Disord* 2022;63:S2211-0348(22)00374-1.
- 18 Prakash RS, Schirda B, Valentine TR, et al. Emotion dysregulation in multiple sclerosis: Impact on symptoms of depression and anxiety. *Mult Scler Relat Disord* 2019;36:S2211-0348(19)30379-7.
- 19 Hadoush H, Alawneh A, Kassab M, *et al.* Effectiveness of nonpharmacological rehabilitation interventions in pain management in patients with multiple sclerosis: Systematic review and metaanalysis. *NeuroRehabilitation* 2022;50:347–65.
- 20 Riemenschneider M, Hvid LG, Ringgaard S, *et al.* Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES). *Mult Scler* 2022;28:1620–9.
- 21 Riemenschneider M, Hvid LG, Petersen T, *et al.* Exercise therapy in early multiple sclerosis improves physical function but not cognition: secondary analyses from a randomized controlled trial. *Neurorehabil Neural Repair* 2023;37:288–97.
- 22 Khan F, Amatya B. Rehabilitation in multiple sclerosis: a systematic review of systematic reviews. *Arch Phys Med Rehabil* 2017;98:353–67.
- 23 Strober LB. Quality of life and psychological well-being in the early stages of multiple sclerosis (MS): Importance of adopting a biopsychosocial model. *Disabil Health J* 2018;11:555–61.
- 24 Martin S, Kihlbom U, Pasquini G, et al. Preferences and attitudes regarding early intervention in multiple sclerosis: A systematic literature review. *Mult Scler Relat Disord* 2024;92:S2211-0348(24)00719-3.
- 25 Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs 2008;62:107–15.
- 26 Tencer T, Will O, Kumar J, et al. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment. *Curr Med Res Opin* 2021;37:1589–98.
- 27 Tatlock S, Sully K, Batish A, et al. Individual differences in the patient experience of Relapsing Multiple Sclerosis (RMS): a multi-country qualitative exploration of drivers of treatment preferences among people living with RMS. *Patient* 2023;16:345–57.
- 28 Reen GK, Silber E, Langdon DW. Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review. *J Neurol Sci* 2017;375:107–22.
- 29 Hoffmann O, Paul F, Haase R, et al. Preferences, adherence, and satisfaction: three years of treatment experiences of people with multiple sclerosis. Patient Prefer Adherence 2024;18:455–66.
- 30 Marziniak M, Brichetto G, Feys P, et al. The use of digital and remote communication technologies as a tool for multiple sclerosis management: narrative review. JMIR Rehabil Assist Technol 2018;5:e5.
- 31 Learmonth YC, Galna B, Laslett LL, et al. Improving telehealth for persons with multiple sclerosis - a cross-sectional study from the Australian MS longitudinal study. *Disabil Rehabil* 2024;46:4755–62.
- 32 Amato MP, Portaccio E, Goretti B, et al. Cognitive impairment in early stages of multiple sclerosis. *Neurol Sci* 2010;31:S211–4.
- 33 Portaccio E, Grossi P, Bellomi F, et al. Meaningful cognitive change for the minimal assessment of cognitive function in multiple sclerosis. *Mult Scler* 2024;30:868–76.
- 34 Komar A, Dickson K, Alavinia M, et al. Effects of mindfulnessbased interventions on cognition in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry 2024;15:1339851.
- 35 Lenne B, Donze C, Massot C, *et al.* Impact of physical activity, physical fitness and exercises on cognitive impairment in patients with multiple sclerosis: A review of evidence and underlying mechanisms. *Rev Neurol (Paris)* 2024;180:583–98.
- 36 Rahmani M, Rahimian Boogar I, Talepasand S, *et al.* Comparing the effectiveness of computer-based, manual-based, and combined

#### **Open** access

cognitive rehabilitation on cognitive functions in relapsing-remitting multiple sclerosis patients. *Basic Clin Neurosci* 2020;11:99–110.

- 37 Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: A review. *Autoimmun Rev* 2020;19:S1568-9972(20)30064-1.
- 38 van Munster CEP, Uitdehaag BMJ. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs 2017;31:217–36.
- 39 Capanna C, Stratta P, Collazzoni A, et al. Social connectedness as resource of resilience: Italian validation of the social connectedness scale-revised. J Psychopathol 2013;19:320–6.
- 40 Webb EJD, Meads D, Eskyte I, et al. A systematic review of discretechoice experiments and conjoint analysis studies in people with multiple sclerosis. *Patient* 2018;11:391–402.
- 41 Lynd LD, Traboulsee A, Marra CA, et al. Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a bestworst scaling study. *Ther Adv Neurol Disord* 2016;9:287–96.
- 42 Doyle L, Brady A-M, Byrne G. An overview of mixed methods research – revisited. J Res Nurs 2016;21:623–35.
- 43 Timans R, Wouters P, Heilbron J. Mixed methods research: what it is and what it could be. *Theor Soc* 2019;48:193–216.

- 44 Garcia-Dominguez JM, Muñoz D, Comellas M, et al. Patient preferences for treatment of multiple sclerosis with diseasemodifying therapies: a discrete choice experiment. Patient Prefer Adherence 2016;10:1945–56.
- 45 Rosato R, Testa S, Oggero A, *et al.* Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients. *Qual Life Res* 2015;24:2173–82.
- 46 Dalgas U, Langeskov-Christensen M, Stenager E, et al. Exercise as medicine in multiple sclerosis-time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr Neurol Neurosci Rep 2019;19:1–12.
- 47 Gitman V, Moss K, Hodgson D. A systematic review and metaanalysis of the effects of non-pharmacological interventions on quality of life in adults with multiple sclerosis. *Eur J Med Res* 2023;28:294.
- 48 Lex H, Weisenbach S, Sloane J, et al. Social-emotional aspects of quality of life in multiple sclerosis. *Psychol Health Med* 2018;23:411–23.
- 49 Gil-González I, Martín-Rodríguez A, Conrad R, *et al.* Quality of life in adults with multiple sclerosis: a systematic review. *BMJ Open* 2020;10:e041249.